Latest Breaking News On - Drugs comptroller general - Page 1 : comparemela.com

Bharat Biotech s Intranasal Vaccine Receives DCGI Approval For Last-Stage Trials As Booster Shots

Bharat Biotech s Intranasal Vaccine Receives DCGI Approval For Last-Stage Trials As Booster Shots
swarajyamag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from swarajyamag.com Daily Mail and Mail on Sunday newspapers.

Serum institute of indiaBharat biotechDrugs comptroller generalSerum instituteDrugs controller general of india dcgiIntranasal vaccineCovid 19 booster dose

Covid-19 wrap-up: India vaccinates 70% adults with first dose

India on Monday achieved another milestone of vaccinating 70 per cent of the target population with the first vaccine dose against Covid-19. The country has fully vaccinated over 25 per cent of the target population of 95 crore.

Tamil naduAndhra pradeshUnited kingdomZydus cadilaRandeep guleriaMahanagara palikeKrishna ellaUnion health ministryFamily welfare departmentj radhakrishnanDevelopment officeIndia institute of medical sciencesBruhat bengaluru mahanagara palikeBharat biotechDrugs comptroller generalBoris johnson ledUnited kingdom foreign

Bharat Biotech submits Covid vaccine trial data for ages 2-18 to DCGI: Report

Covaxin manufacturer Bharat Biotech has submitted the trial data for its coronavirus vaccine in 2-18-year-olds to Drugs Comptroller General of India (DCGI) for approval, chairman and managing director Krishna Ella told a TV channel on Saturday.

Andhra pradeshKrishna ellaSerum instituteBharat biotechDrugs comptroller generalZydus cadilaCovid 19

Monthly Production Of Covishield And Covaxin To Shoot Up To 10 Crore And 7 8 Crore Respectively By August 2021

Monthly Production Of Covishield And Covaxin To Shoot Up To 10 Crore And 7 8 Crore Respectively By August 2021
swarajyamag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from swarajyamag.com Daily Mail and Mail on Sunday newspapers.

V krishna mohanPrakash kumar singhUnion health ministryRegulatory affairsDepartment of pharmaceuticals rajneesh tingalSerum institute of indiaMinistry of health dr mandeep bhandariMinistry of scienceSerum instituteBharat biotechDrugs comptroller generalBiotech director drv krishna mohanRegulatory affairs directorKumar singhJoint secretaryPharmaceuticals rajneesh tingal

COVID vaccine: Amid concerns over vaccine shortages, Centre paves way for foreign-manufactured vaccines: What this means

Updated Apr 14, 2021 | 11:59 IST The decision on Tuesday arrived shortly after the Drugs Comptroller General of India (DGCI) granted emergency-use authorisation to the Russian-made Sputnik V vaccine. Representational image. | Photo Credit: iStock Images Key Highlights In making the latest decision, the Centre has invoked a clause in the 2019 mandate which allows Indian regulators to fast-track vaccine approvals if they have already been approved by a national regulator of a different country The first 100 beneficiaries of a foreign-manufactured vaccine will need to be assessed for 100 days to determine safety outcomes before rollouts can be expanded in the country The announcement paves the way for the entrance of foreign-made vaccines like that of Johnson & Johnson s (which already has a link-up with India s Biological E), Novavax (which has a link-up with SII) and Pfizer s

United kingdomUddhav thackerayDr reddy labsEuropean unionSerum institute of indiaWorld health organisationPhoto creditStock imagesWorld healthDrugs comptroller generalMaharashtra chief minister uddhav thackerayNew drugsClinical trials rulesSerum instituteCovid vaccineSputnik v